drugset / Trial / NCT00515528
Vaccination Plus Ontak in Patients With Metastatic Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if an experimental melanoma vaccine can produce an immune response in patients with metastatic melanoma, and if combining this vaccine with the drug Ontak can improve these immune responses. It is also hoped that this will lead to tumor shrinkage.
Timeline
- Start
- 2007-04-23
- Primary completion
- 2016-03
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 4-peptide melanoma vaccine | Vaccine | 125 ug | Subcutaneous |
| Subject | 4-peptide melanoma vaccine | Vaccine | 250 ug | Subcutaneous |
| Subject | denileukin diftitox | Protein / enzyme biologic | 18 ug/kg | Intravenous |